Contribute Try STAT+ Today

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Prescription Politics By Lev Facher

More than two-thirds of Congress cashed a pharma campaign check in 2020, new STAT analysis shows

A new STAT analysis shows that more than two-thirds of Congress cashed a check from the pharmaceutical industry ahead of the 2020 election.

Biogen

Pharmalot By Ed Silverman

Poll: Most Americans believe new Alzheimer’s drug is effective, but many are concerned with FDA process

money pile

Pharmalot By Ed Silverman

Billions spent on prescription drug ads may have increased Medicare spending

Cash on yellow background

Pharmalot By Ed Silverman

Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge

Porous Silica Nanoparticles

Biotech By Elizabeth Cooney

How nanotechnology helps mRNA Covid-19 vaccines work

All Coverage

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Biden to spend $3 billion to develop Covid-19 pills; most Americans believe the new Alzheimer’s drug will be effective

advertisement

Pharmalot By Ed Silverman

Pharmalittle: CureVac Covid-19 shot was 47% effective in a trial; pricey brain cancer drug no longer covered by Medicare

lab tech holding vials adaptive trials

Pharmalot By Ed Silverman

American Medical Association delegates vote to support controversial Covid-19 IP waiver

Pharmalot By Ed Silverman

Pharmalittle: Regeneron Covid-19 drug cuts risk of death in some patients; bills reintroduced to help develop new antibiotics

CO Senator Michael Bennet

Exclusive By Ed Silverman

Lawmakers revive legislation to accelerate the development of new antibiotics

FDA stop sign

Pharmalot By Ed Silverman

‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval

Amazon PBM shopping

Pharmalot By Ed Silverman

Centene to pay $143 million to two states to settle allegations of overcharging Medicaid

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca antibody therapy failed to prevent Covid-19; former FDA Commish Hahn joins Moderna backer

vials & syringe

Pharmalot By Ed Silverman

Mississippi becomes the first state to jointly sue drug makers and PBMs over the cost of insulin

Pharmalot By Ed Silverman

Pharmalittle: Novavax says Covid-19 shot is highly effective; doctors scramble to advise patients on Alzheimer’s drug

China Glaxo Investigation

Biotech By Adam Feuerstein

GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos

2020 Biogen

Pharmalot By Ed Silverman

‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: A third FDA panel member resigns over Alzheimer’s drug approval; agency’s decision hardens opposition to Woodcock

Pharmalot By Elizabeth Cooney

Pharmalittle: U.S. to donate 500 million Covid vaccine doses; WTO to step up talks on waiving IP protection for Covid shots

Worldwide Covid-19 vaccinations

Pharmalot By Ed Silverman

WTO members agree to step up talks about Covid-19 intellectual property proposals

Pharmalot By Ed Silverman

Pharmalittle: Biogen and FDA at odds over a key Alzheimer’s drug trial; Senate Dems craft their own drug-pricing bill

Prescription Politics By Lev Facher

Pharma funded more than 2,400 state lawmaker campaigns in 2020, new STAT analysis finds

Regeneron

Pharmalot By Ed Silverman

Regeneron shareholders urged to boot board member over executive pay practices

Pharmalot By Ed Silverman

Pharmalittle: FDA rewrites rulebook in approving Alzheimer’s drug; Biogen’s price for the drug will strain Medicare

Aducanumab study

Pharmalot By Ed Silverman

‘The price is bewildering’: The cost of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks

aducanumab Alzheimers breakthrough

First Opinion By Dana Goldman and Darius Lakdawalla

FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver